Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life Acne-like skin rash is a common side effect from colorectal ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...

A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...

CHICAGO – Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash compared ...

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...

Please provide your email address to receive an email when new articles are posted on . A 3 1/2-year-old girl who is in the maintenance phase of chemotherapy for leukemia is seen for a moderately ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...